VSTMVerastem, Inc.Not started yet
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Low Grade Ovarian Serous Adenocarcinoma · Ovarian Cancer
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Worry score12
Score over time
- Stage
- Phase 2
- Patients
- 2 (planned)
- Started
- Aug 3, 2026
- Main results expected
- Aug 1, 2027
- Fully finished
- Aug 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Duration of Treatment Exposure to Avutometinib in Combination With Defactinib
Measured over: Until treatment discontinuation (approximately 20 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT07747506 · record last updated 2026-08-05 · checked 2026-11-09 15:42 UTC